The achieved tumor uptake of [177Lu]Lu-DOTA-MGS8 and [111In]In-DOTA-MGS8 (~35% IA/g and ~43% IA/g) was superior to the improvement in tumor uptake, which was previously reported for [111In]In-DOTA-MG11 injected in combination with the neprilysin inhibitor phosphoramidon (~15% IA/g) [16,30]. The gene discussed is MME; the disease is neoplasm.